Taking care of a dog is a big responsibility, no doubt. And yes, sometimes it can even be a little frustrating. My six-month-old Shih-Tzu, Alfie, is still convinced that Balenciaga 3XLs are the ultimate chew toy. (He’s on a real shoelace kick, so I get it.) But most every dog owner would agree that the […]

In the new study, co-author Laura Pritschet, a PhD student, and her team determined that along with a rise in estrogen and progesterone, the gray matter in the pregnant woman’s brain deteriorated over the course of her gestation, starting as early as the ninth week.1 Neuroanatomical changes observed over the course of a human pregnancy. […]

Enveric Biosciences Inc, a biotechnology company specializing in neuroplastogen therapeutics for mental health conditions, has entered into a licensing agreement with MycoMedica Life Sciences. Enveric will out-license its EVM201 program, including the drug candidate EB-002 (formerly EB-373), to MycoMedica. The partnership is set to bring forward the development of EB-002, a synthetic prodrug of psilocin for […]

The biotech will concentrate on its “trip-free” compound, especially following recent FDA concerns on psychedelic trial designs. Enveric Biosciences (NASDAQ: ENVB) agreed to license one of its experimental psychedelic drug candidates to MycoMedica Life Sciences in a deal worth as much as $62 million, as the biotech company keeps its eye on its non-hallucinogenic treatments.

Many biotech startups decide to operate in what is known as “stealth mode”. Here, they are almost invisible to the outside world, able to look inward and avoid the distractions and tribulations that can potentially arise from being in the public eye. But what exactly is stealth mode and what benefits does it offer young […]

Enveric Biosciences ENVB recently announced that research highlighting the Company’s lead compound, EB-003, is being presented at the 7th Neuropsychiatric Drug Summit. EB-003 is a promising neuroplastogenic and non-hallucinogenic N, N-Dimethyltryptamine (DMT) analog drug candidate that elicited beneficial outcomes in preclinical models of anxiety and depression. The conference is being held at the Hilton Boston […]

Neuroplastogen biotech company Enveric Biosciences ENVB has presented research highlighting its lead compound, EB-003 at the 7th Neuropsychiatric Drug Summit showing beneficial outcomes in preclinical models of anxiety and depression.

The recent FDA rejection of MDMA-assisted therapy for PTSD put forth by Lykos Therapeutics has left the psychedelic drug development and mental health communities at a critical juncture, reigniting discussions about the future of innovative mental health treatments. As the industry faces this significant setback, the question emerges: where do we go now?

Psychedelics biotech Enveric Biosciences ENVB announced positive preclinical results of its EB-003 drug candidate to be delivered via oral administration. EB-003 is a new, neuroplastogenic molecule designed to treat serious mental health disorders without the hallucinogenic effect typically associated with DMT (N,N-Dimethyltryptamine) and other psychedelic compounds. The results indicate that oral administration of EB-003 provides […]

Enveric Biosciences, a forward-thinking biotechnology company specializing in neuroplastogenic treatments for neuropsychiatric disorders, has announced preclinical results that underscore the potential of their novel drug candidate, EB-003. These findings, detailed in a recent press release, highlight the drug’s oral bioavailability and significant brain exposure, positioning it as a promising treatment for severe mental health conditions.